A synthetic peptide for use as a blocking control in assays to test for specificity of F8 antibody, Alternative Names: F8 control peptide, F8 antibody Blocking Peptide, Anti-F8 Blocking Peptide, coagulation factor VIII, procoagulant component Blocking Peptide, AHF Blocking Peptide, DXS1253E Blocking Peptide, F8B Blocking Peptide, F8C Blocking Peptide, FVIII Blocking Peptide, HEMA Blocking Peptide, F8, F-8, F 8, F-8 Blocking Peptide, F 8 Blocking Peptide
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
Factor VIII (F8)
(Coagulation Factor VIII (F8))
Hintergrund
This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation, factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.